19.15
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
MiNK Therapeutics Inc. Stock Analysis and ForecastConsistent triple returns - Autocar Professional
What drives MiNK Therapeutics Inc. stock priceUnprecedented profits - jammulinksnews.com
What analysts say about MiNK Therapeutics Inc. stockBreakneck growth rates - jammulinksnews.com
Is MiNK Therapeutics Inc. a good long term investmentFree Investment Timing Strategies - jammulinksnews.com
(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
How MiNK Therapeutics Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser
MiNK Therapeutics (NASDAQ:INKT) Upgraded at B. Riley - Defense World
MiNK Therapeutics Announces Clinical Trial Success - MSN
MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress - Oncodaily
MiNK Therapeutics (NASDAQ:INKT) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Mink Therapeutics Shares Slide After Announcing $50 Million Stock Offering - MSN
MiNK Therapeutics (NASDAQ:INKT) Cut to Neutral at HC Wainwright - Defense World
Mink Therapeutics stock tumbles on $50 million stock offering - Investing.com
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
What makes MiNK Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
Why MiNK Therapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright - Investing.com Canada
MiNK Therapeutics Plummets 29%—What’s Driving the Sell-Off? - AInvest
MiNK Therapeutics Plummets 28.59% — What’s Driving the Sell-Off? - AInvest
Mink Therapeutics stock tumbles on $50 million stock offering By Investing.com - Investing.com Nigeria
MiNK Therapeutics publishes research on CAR-iNKT cell therapy By Investing.com - Investing.com South Africa
MiNK Therapeutics enters $50 million at-the-market sales agreement with B. Riley Securities By Investing.com - Investing.com South Africa
MiNK Therapeutics enters $50 million at-the-market sales agreement with B. Riley Securities - Investing.com Canada
MiNK Therapeutics Publishes Peer-Reviewed Article Highlighting Innovations in CAR-iNKT Cell Therapies for Solid Tumors - Nasdaq
MiNK Therapeutics Announces Frontiers in Immunology - GlobeNewswire
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - TradingView
Revolutionary iNKT Cell Therapy Achieves 2-Year Complete Remission in Treatment-Resistant Cancer - Stock Titan
MiNK Therapeutics tumbles after $50 mln stock offering filing - TradingView
INKT’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
MiNK Therapeutics Enters $50M Sales Agreement with B. Riley - TipRanks
MiNK Therapeutics Plunges 24.87% After William Blair Downgrade - AInvest
INKT sets up $50M ATM with B. Riley, adds financing flexibility | INKT SEC FilingForm 8-K - Stock Titan
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):